dose escalation trial

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Korean chipmakers SK Hynix makes strides in CXL technology, escalating rivalry

SK Hynix Inc., the leading global high-bandwidth memory (HBM) chip provider, has moved faster than its rivals in the commercialization of the next-g...

Bio & Pharma SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

Steel South Korea to levy 38% anti-dumping duties on Chinese steel products

South Korea plans to impose up to 38% provisional anti-dumping duties on Chinese hot-rolled steel plates starting next month, judging that those pro...

Business & Politics China likely to lift ban on South Korea’s K-wave as early as May

BEIJING – China will likely lift its ban on Hallyu, or Korean popular culture in the country, as early as May, moving away from its “wol...

Food & Beverage Korean bakery giant SPC to build $160 mn US plant as tariff war escalates

SPC Group, the operator of South Korea’s largest bakery chain Paris Baguette as well as Paris Croissant, SPL, Dunkin and SPC GFS, is building ...

Korean startups Mediaiplus aims to be the Amazon of clinical trials

Mediaiplus Inc., South Korea’s only provider of data analytics and contract research organization (CRO) matching services for clinical trials,...

Shipping & Shipbuilding HD Hyundai may nearly double shipbuilding capacity in Vietnam

HD Hyundai Co., the world’s second-largest shipbuilder, is likely to nearly double its vessel construction capacity in Vietnam to meet surging...

Korean food S.Korea’s premium kimchi war escalated by luxury hotels

Kimchi, Koreans’ staple food throughout millennia, has become a new, lucrative revenue source for the country’s luxury hotel chain opera...

Tech, Media & Telecom LG’s telecom unit looks to lure foreigners with more K-pop-themed shops

LG Uplus Corp., South Korea’s No. 3 mobile carrier, is set to lure foreign customers by opening K-pop-themed stores in the country's major sho...

Bio & Pharma Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials

Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...

Bio & Pharma Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

K-pop HYBE conflict vs NewJeans label set to escalate into legal battle

HYBE Co., the company behind boy band BTS, has reported Min Hee-jin, the chief of popular girl group NewJeans’ label ADOR, to police for inves...

Korean chipmakers Samsung gains upper hand vs Netlist in $303 million patent dispute

Samsung Electronics Co. has taken the upper hand in its ongoing legal battle against Netlist Inc. over memory chip module patent infringement allega...

Bio & Pharma Global quest to find modern elixirs enters new chapter

NEW YORK/ BOSTON – Longevity has long been the dream of humankind. China’s first emperor Qin Shi Huang was obsessed with finding magic e...

Bio & Pharma SK Bioscience exports Sky Cellflu to Thailand

South Korea's SK Bioscience Co. announced on Thursday that it has shipped about 440,000 doses (for single-dose administration) of its cell-cultured ...

Bio & Pharma Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar

South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...

Bio & Pharma JW Pharma takes gout drug Epaminurad to Malaysia for phase 3

South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...

Bio & Pharma LG Chem out-licenses obesity drug candidate to US firm

LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...

Bio & Pharma MedPacto gets FDA OK for colorectal cancer drug clinical trial

South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...

Bio & Pharma CGBio gets FDA approval for Novosis Putty

South Korea's bio-regenerative medical firm CGBio announced on Tuesday that its Novosis Putty has been designated as a breakthrough device by the US...

Leadership & Management MBK raises Hankook bid price, asks FSS to probe Cho's stock purchase

The sibling rivalry for control of Hankook & Company Co., the holding firm of South Korea’s largest tire maker Hankook Tire & Techno...

Bio & Pharma SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine

South Korea's SK Bioscience Co. announced on Monday that it submitted the Investigational New Drug (IND) application for the Phase 3 clinical trial ...

Bio & Pharma Celltrion applies for approval in Europe for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...

Bio & Pharma NKMax to perform first tests on dementia cell therapy in US

NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...

Bio & Pharma Hanmi Pharma’s Phase 3 trials for anti-obesity medicine approved

South Korea’s Hanmi Pharmaceutical Co. on Monday said the Ministry of Food and Drug Safety approved Phase 3 clinical trials for the company&...

Bio & Pharma Humedix gets gov't OK for trials of dementia candidate drug

South Korea’s Humedix Co., a developer of biological and pharmaceutical products, on Tuesday said it received approval from the Ministry of Fo...

Bio & Pharma NKMax's US subsidiary listed on Nasdaq

South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...

Bio & Pharma JW Pharma to conduct Phase 3 trials in Thailand for gout treatment

South Korea's JW Pharmaceutical Corp. on Thursday said it received approval from Thailand's Food and Drug Administration to conduct Phase 3 clinical...

Bio & Pharma Genome & Co.’s bile duct cancer drug candidate enters Phase 2 trials

Genome & Company, a South Korean developer of microbiome-based drugs, on Tuesday said its GEN-001, a leading immunotherapy drug candidate for bi...